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Abstract Tobacco plants were engineered to express SMAP-
29, a mammalian antimicrobial peptide of innate immunity, as
fusion protein with modified vacuolar membrane ATPase intein.
The peptide was purified taking advantage of the intein-mediated
self-cleaving mechanism. SMAP-29 was immunologically de-
tected in the chromatographic eluate and appeared tightly bound
to copurified plant proteins. Electrophoretic separation under
disaggregating conditions indicated that the recombinant peptide
was cleaved off by intein at the expected site and an overlay gel
assay demonstrated that the peptide retained antimicrobial
activity. These results indicate that a modified intein expression
system can be used to produce pharmaceutical peptides in
transgenic plants. # 2002 Published by Elsevier Science B.V.
on behalf of the Federation of European Biochemical Societies.
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1. Introduction
Inteins are protein splicing elements that can catalyse their
self-excision from a precursor polypeptide triggering the fu-
sion of the regions £anking the cleavage site (exteins) [1]. The
intein-mediated self-cleaving mechanism has recently been ex-
ploited to purify recombinant proteins from bacterial cultures.
Heterologous proteins can be synthesised in fusion to inteins
that have been genetically engineered to promote a control-
lable ¢ssion of peptide bond at either terminus of intein itself.
The release of the target protein can be obtained simply by
adding nucleophilic agents such as 1,4-dithiothreitol (DTT),
hydroxylamine or cysteine to generate the thioester intermedi-
ate required for the initiation of self-catalytic intein-mediated
cleavage reaction. This strategy o¡ers the main advantage that
the protein of interest can be isolated from the bulk of cell
extracts by a single-step puri¢cation [2,3].
The intein-based systems can be suitably designed for the
production of many xenogenic proteins, such as hormones,
enzymes, anti-viral and anti-infective peptides that need to
be puri¢ed or downstream processed in order to be used as
biopharmaceuticals [4,5]. The increasing demand for biophar-
maceutical products has encouraged the search for new and
commercially competitive systems for producing recombinant
proteins. From this point of view, plants are an interesting
source of heterologous proteins as they are able to replace
almost any eukaryotic metabolic pathway and their applica-
tion o¡ers several advantages such as low production costs
and lack of contamination from transmissible pathogen
agents [6].
The aim of this work was to study the applicability of a
self-cleaving intein expression system for producing xenogenic
proteins in transgenic plants. The modi¢ed vacuolar mem-
brane ATPase (VMA) intein expression/puri¢cation system
has been applied to obtain recombinant SMAP-29, an K-heli-
cal cathelicidin peptide displaying a powerful antimicrobial
activity [7^12], from transgenic tobacco plants. SMAP-29
was identi¢ed in sheep myeloid cells [7] and proved to be
highly e¡ective in vitro against a broad spectrum of bacteria
and fungi [8]. It is noteworthy that SMAP-29 was also e¡ec-
tive against antibiotic-resistant bacterial strains as well as
Pseudomonas aeruginosa, a pathogen causing severe respira-
tory infections in cystic ¢brosis patients [7^12]. Naturally oc-
curring antimicrobial peptides have raised considerable inter-
est for their potential as lead compounds for the development
of new anti-infective agents [13,14] and they thus represent a
good target for the application of intein-based systems in
plants. The rationale of our work was to construct a trans-
formation vector containing a transgene cassette made of
SMAP-29 coding sequence [7] in conjunction with the modi-
¢ed VMA-1 intein cDNA derived from Saccharomyces cere-
visiae, and the nucleotide tract encoding the chitin binding
domain (CBD) of Bacillus circulans as a⁄nity tag [2]. The
Agrobacterium-mediated integration of the arti¢cial gene
into tobacco plant genome led to the expression of the fusion
protein in transgenic plants. The L-conglycinin transit peptide
(GenBank AJ276118) has been designed to address the fusion
protein to endoplasmic reticulum and then to the apoplast
compartment, in order to allow its recovery in the bulk of
soluble proteins. The SMAP^intein^CBD polypeptide could
be ¢nally isolated by a⁄nity chromatography using a chitin-
derived matrix able to bind the CBD tag. The addition of
nucleophilic compounds inducing the intein-mediated protein
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self-cleavage reaction led to the release of recombinant pep-
tide.
2. Materials and methods
2.1. Plant expression vector, pBI-SMAP
Primer sequences used to build the vector (Fig. 1) and/or to per-
form molecular testing were:
1. 5P-CATTTGGAGAGACACCGGGG-3P
2. 5P-CCCGGGATGATGAGAGCGCGGTTC-3P
3. 5P-CTTAAGAGGGGACTTCGAAGACTG-3P
4. 5P-TCTAGACCCGGGTGCTTTGCCAAGGGTACC-3P
5. 5P-CGATCGGGGAAATTCGAGCTC-3P
6. 5P-GAGCTCTCATTGAAGCTGCCACAAGG-3P
7. 5P-CCCGGGCCCAGCTATTCTGATTATT-3P
8. 5P-CTTAAGGAGGTTGCAACGAG-3P
9. 5P-AATATACGCTATTGGAGCTGG-3P
10. 5P-ATGGCTCATTAAATCAGTTAT-3P
The intein^CBD sequence, isolated by PCR from pCYB 1 plasmid
(NEB, Beverly, MA, USA) using primers 4 and 6, was cloned into
pCR 2.1-TOPO vector (Invitrogen, Groningen, The Netherlands).
Primer 4 introduced the XbaI and SmaI sites, whereas primer 6 the
SacI site. XbaI and SacI were used for further cloning of intein^CBD
(1572 bp) into pBI121 binary vector (Clontech, Palo Alto, CA, USA)
after removal of the uidA gene. The intein^CBD encoding sequence
was checked by the GeneBlast program to verify the compatibility
between yeast and tobacco codon usage.
The L-conglycinin transit peptide sequence (192 bp) (GenBank
AJ276118) was isolated by PCR from soybean genomic DNA using
primers 2 and 8. Primer 2 introduced a SmaI site, while the sequence
naturally terminated with the BfrI site.
The SMAP-29 cDNA was isolated from sheep myeloid cell RNA by
reverse transcription (RT)-PCR as [7] and cloned in BlueScript KS+
vector (Stratagene, San Diego, CA, USA). The whole template was
ampli¢ed with primers 3 and 7 and cloned into pGEM-T (Promega,
Madison, WI, USA). Primers added the BfrI and SmaI sites, respec-
tively. All the above-mentioned sequences were veri¢ed on both
strands.
The 5P terminus of SMAP-29 (99 bp) was fused to the 3P terminus
of the transit peptide sequence using the BfrI site. This construct
encoding L-conglycinin transit peptide and SMAP cDNA was then
positioned at the 5P end of intein^CBD in the pBI121 vector using the
SmaI site. The PCR template spanning the whole transgene cassette
and obtained using primers 1 and 5 is 1901 bp long.
The ¢nal pBI-SMAP vector was then used to transform tobacco
(Nicotiana tabacum L., cv. Xanthi) leaf discs [15] with Agrobacterium
tumefaciens EHA105 strain. Among putatively transformed (kanamy-
cin-resistant) plants, 20, denoted T13T20, were chosen for molecular
testing.
2.2. PCR and Southern blotting of genomic DNA
PCR assays were performed with genomic DNA using primers 1
and 5. DNA size was evaluated by Molecular Weight Marker III
(Boehringer-Mannheim, Germany). For Southern blotting, 10 Wg of
genomic DNA digested with HindIII (which cuts at the polycloning
site and at the 467th base of intein sequence) was processed as in [16].
SMAP^intein cDNA probe was obtained by PCR ampli¢cation with
primers 3 and 6.
2.3. RT-PCR and Northern blotting of total RNA
Total RNA, extracted from leaf samples by RNAgents Total RNA
Isolation System (Promega), was retrotranscribed and ampli¢ed by
Access RT-PCR System (Promega) using 2 or 3 as forward and 6
as reverse primers. RNA size was evaluated by Molecular Weight
Marker III (Boehringer-Mannheim). For Northern blotting, 30 Wg
of total RNA separated under denaturing conditions was transferred
onto a nylon membrane and hybridised with the above-mentioned
SMAP^intein cDNA probe. After autoradiography cDNA probe
was stripped o¡ and RNA blots rehybridised with control ribosomal
cDNA 550 bp probe; the latter was obtained by RT-PCR using prim-
ers 9 and 10.
2.4. Protein chromatography
Leaf tissue (5 g), powdered under liquid nitrogen, was incubated for
1 h at 4‡C with 10 ml extraction bu¡er (50 mM bis-tris-propane
(BTP), pH 9, 20 mM NaCl, 1 mM EDTA, 1% Triton X-100, 5%
glycerol) containing Protease Inhibitor Cocktail (P9599 Sigma-Al-
drich, St. Louis, MO, USA). The homogenate was centrifuged at
12 000Ug for 30 min at 4‡C, and the supernatant centrifuged again
at 35 000Ug for 1 h at 4‡C. The clari¢ed extract was subjected to a
G-50 Sephadex column to separate intein fusion protein from the pos-
sibly in vivo cleaved peptide. The £ow-through was concentrated and
desalted using Centriplus YM-10 (Amicon, Millipore, Bedford, MA,
USA). The extract was diluted 1:1 with column bu¡er (50 mM BTP,
pH 9, 500 mM NaCl, 1 mM EDTA, 0.1% Triton X-100), loaded onto
a 10 ml column of chitin resin (NEB) and washed with 10 volumes of
column bu¡er. The intein-mediated self-cleavage reaction was induced
by 24 h incubation at 4‡C in cleavage bu¡er (50 mM BTP, pH 9, 20
mM NaCl, 1 mM EDTA) containing 50 mM DTT. The chromato-
graphic eluate was collected and ultra¢ltrated using YM-1 Amicon
(Millipore) membrane. Samples were lyophilised and resuspended in
0.1% tri£uoroacetic acid.
2.5. Protein electrophoresis and immunological assays
Protein samples were separated by sodium dodecyl sulphate^poly-
acrylamide gel electrophoresis (SDS^PAGE) or acid-acetic-urea
(AAU)^PAGE as in [17]. For fusion protein detection, 2 mg of crude
extract proteins was mixed with 200 Wl of chitin resin and incubated
for about 4 h, at 4‡C. The protein fraction bound to the chitin beads
was recovered, washed with column bu¡er and stripped o¡ with 200
Wl of 6 M guanidinium containing 0.5% (w/v) N-lauryl sarcosine.
After separation from the beads and acetone precipitation, proteins
were dissolved in SDS^PAGE sample loading bu¡er and electropho-
resed.
Western blotting and enzyme-linked immunosorbent assay (ELISA)
were done following standard molecular techniques [16]. Brie£y, for
Western blotting, 200 ng of puri¢ed protein or synthetic peptide was
electroblotted to Immobilon PSQ membrane (Millipore). Blots were
probed with 1:1000 dilution of polyclonal SMAP-29 antiserum, raised
in rabbit, 1:10000 dilution of goat anti-rabbit immunoglobulins^per-
oxidase conjugate (Vector, Burlingame, CA, USA) and developed us-
ing the Supersignal PicoWest Chemoluminescent Substrate (Pierce,
Rockford, IL, USA) detection system. For ELISA, protein samples
were diluted in 0.1 M sodium bicarbonate bu¡er, pH 9.6, and seeded
in a 96-well microtiter plate. After overnight incubation at 4‡C, de-
tection was made with 1:1000 dilution of rabbit polyclonal SMAP-29
antiserum, 1:5000 goat anti-rabbit biotinylated immunoglobulins
(Vector). The reaction was enhanced by streptavidin^peroxidase con-
jugate (Sigma-Aldrich) and detection made using the Sigma-Fast p-ni-
trophenyl-L-phosphatase (Sigma-Aldrich) colorimetric system. Syn-
thetic SMAP-29 peptide (RGLRRLGRKIAHGVKKYGPTVLRII-
RIA), chemically obtained by a solid phase method [8], was used as
positive control. The molecular size markers used were Sigma M
3546-Ultra Low Range (Sigma-Aldrich, St. Louis, MO, USA) and
Bio-Rad 161-0304 Low Range (Hercules, CA, USA).
2.6. Gel overlay assay
The assay was carried out according to [18] with some modi¢ca-
tions. A single clone of JM101 lacZþ Escherichia coli bacterial strain
containing self-ligated pGEM-T vector (Promega) was grown over-
night at 37‡C in full strength Luria^Bertani (LB) medium. A mid-
logarithmic phase subculture was obtained from an aliquot of sta-
tionary phase culture by a 2 h incubation at 37‡C in fresh medium.
Bacteria were collected by centrifugation, washed and resuspended in
10 mM NaPi bu¡er, pH 7.4. According to the relation OD620 nm
0.2= 5U107 colony-forming units (CFU)/ml, 4U106 CFU/ml was
added to 1% (w/v) agarose/LB medium containing 5-bromo-4-
chloro-3-indolyl-L-D-galactopyranoside and isopropyl-L-D-thiogalac-
topyranoside and poured into a Petri dish to form an underlayer
gel, 1 mm deep.
AAU minigel and protein samples (500 ng of puri¢ed protein, 1 Wg
of synthetic peptide) were prepared and processed as described in [18].
After protein transfer, underlayer agarose gel was overlayed with a
double-strength LB medium containing 1% (w/v) agarose and incu-
bated for 24 h at 37‡C until the zones of clearing were evident against
the blue background. Bacterial growth inhibition areas were enhanced
by Coomassie staining.
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3. Results and discussion
3.1. Molecular analysis of transgenic tobacco plants
pBI-SMAP vector (Fig. 1) was constructed and used to
achieve transgenic tobacco plants via Agrobacterium infection.
The SMAP^intein^CBD cassette was cloned downstream of
the constitutive enhanced CaMV 35S promoter and the L-con-
glycinin transit peptide encoding sequence. This latter should
address the newly synthesised heterologous protein to the
apoplast.
PCR analysis of genomic DNA con¢rmed the presence of
the full-length transgene (1901 bp) in all the kanamycin-resis-
tant plants, each deriving from an independent transforma-
tion event (Fig. 2A). Southern blotting revealed the insertion
of one to four copies of the transgene in the tobacco genome
(Fig. 2B). All plants produced self-pollinated seeds that gen-
erated kanamycin-resistant progenies. Transgenic DNA was
detected by PCR in the genome of these plants (data not
shown), con¢rming stable inheritance through meiosis.
Transgene expression was demonstrated in transgenic plant
leaves by both RT-PCR and Northern blotting. In the ¢rst
instance, ampli¢cation products corresponding to transgene
coding sequence were obtained (1671 bp) (Fig. 3A). The
lack of any amplicon in a PCR performed using total RNA,
without RT step, ruled out genomic DNA contamination in
the RNA preparations (data not shown). Northern blotting
hybridisation revealed the presence of a messenger RNA band
speci¢cally recognised by SMAP^intein^CBD cDNA probe.
This band was detectable only in RNA samples from trans-
Fig. 1. Transgenic SMAP-29 nucleotide (A) and amino acid (B) sequence. C: pBI-SMAP transformation vector. The numbered arrows refer to
the primers used for PCR and RT-PCR assays and the size of the ampli¢cation products (including the restriction sites added for cloning) is
indicated (TP: L-conglycinin transit peptide; NOS-pro: nopaline synthase promoter; NPT II (Kan R): nopaline phosphotransferase II gene
conferring kanamycin resistance; NOS-ter: nopaline synthase terminator; CaMV 35S: cauli£ower mosaic virus 35S).
Fig. 2. Transgene integration in the genome of transformed tobacco.
A: PCR detection of full-length transgene. B: Southern blotting of
genomic DNA extracted from transgenic plants. M: molecular size
marker, PC: pBI-SMAP (positive control), C: no DNA, NC: un-
transformed tobacco DNA (negative control), T1^T7 : DNA of
transformed tobacco plants, P: transgene SMAP cassette subcloned
in pBI221 vector and digested with HindIII.
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genic plants and was of a size compatible with transgene tran-
script (Fig. 3B).
3.2. Isolation, puri¢cation and analysis of the recombinant
peptide
Transformed tobacco plants were then examined for the
presence of the SMAP-29 intein^CBD polypeptide. The plants
used for this analysis were chosen among the single-copy
transgene lines with the highest transgene expression levels,
as estimated by Northern blotting. The fusion protein was
isolated incubating transgenic leaf homogenates with chitin
beads. The chitin-bound polypeptide was stripped o¡ and
analysed by Western blotting. A rabbit polyclonal SMAP-29
antiserum speci¢cally immunodecorated a 58 kDa band, cor-
responding to SMAP-29^intein^CBD fusion protein (Fig. 4).
To purify SMAP-29 from the fusion protein, leaf crude
extracts were loaded onto a puri¢cation column packed with
chitin resin and the on-column intein-mediated self-cleavage
mechanism was triggered by thiol addition. The CBD a⁄nity
tag was recognised by chitin molecule and allowed the isola-
tion of SMAP-29 intein^CBD polypeptide, while thiol addi-
tion induced the intein-mediated protein splicing, thus causing
release of recombinant peptide. Samples were recovered after
elution and analysed by ELISA. SMAP antiserum revealed
the presence of the peptide in the chromatographic eluate
obtained from transgenic tobacco extracts, whereas no signi¢-
cant signal was found with the untransformed control pro-
cessed under the same conditions (Fig. 5A). ELISA analysis
did not reveal signi¢cant di¡erences in the recovery of re-
combinant SMAP among eluate samples obtained after the
chromatographic puri¢cation of extracts derived from di¡er-
ent plants displaying comparable RNA levels (data not
shown).
Puri¢ed samples were then separated by SDS^PAGE and
subjected to Western blotting. SMAP antiserum detected a
product with an apparent molecular weight (MW) (about 28
kDa) higher than synthetic SMAP-29 (3.2 kDa). The signal
appeared to be speci¢c since no band was detected in the
Fig. 4. Detection of SMAP^intein^CBD fusion protein by Western
blotting with SMAP antiserum. T: transformed plant, NC: untrans-
formed control plant (negative control), M: molecular size marker.
Fig. 3. Transgene expression in transformed tobacco leaves. A: RT-
PCR detection of SMAP^intein^CBD mRNA using primers 3 and
6. B: Northern blotting of total RNA extracted from leaf tissue of
transgenic plants M: molecular size marker, NC: untransformed to-
bacco RNA (negative control), T1^T5 : RNA of transformed tobac-
co plants, P: SMAP^intein^CBD cDNA probe.
Fig. 5. ELISA and Western blotting analysis of the chromatographic eluate derived from puri¢ed tobacco leaf protein extract. A: Detection
and quanti¢cation of transgenic SMAP-29 in the chromatographic eluate by ELISA assay. B: Western blotting of transgenic SMAP eluate
treated with DTT. Lane 1: untransformed plant extract chromatography-puri¢ed eluate; lane 2: DTT-treated transgenic SMAP eluate; lane 3:
transgenic SMAP eluate; lane 4: synthetic SMAP-29; M: molecular size marker.
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untransformed control eluate (Fig. 5B). The electrophoretic
mobility of this product did not correspond to that of the
fusion protein (58 kDa) nor to the unprocessed L-conglycinin
transit peptide joined to SMAP-29. In addition, the occur-
rence of an aspeci¢c cleavage was unlikely, since prolonged
incubation of SMAP eluate in the presence of high DTT con-
centrations (100 mM, 48 h) did not produce additional bands
(Fig. 5B, lane 2).
It has thus been investigated whether the presence of a 28
kDa band might be due to the interaction of recombinant
SMAP-29 with copuri¢ed plant proteins. In fact, the tendency
of cationic peptides to form higher MW complexes in associ-
ation with serum proteins has previously been observed [19^
22]. The ability of SMAP-29 to bind to plant proteins was ¢rst
con¢rmed by incubating the synthetic peptide with the protein
extract derived from the untransformed control. Western blot-
ting demonstrated the added peptide bound to plant proteins,
revealing a band with electrophoretic mobility similar to that
of the complex in which the recombinant SMAP was recruited
(Fig. 6). It is nonetheless worth noting that proteins contained
in rabbit serum were also found to interact with SMAP-29
generating high MW complexes (data not shown).
Several attempts were then made to recover the peptide
from the 28 kDa complex. These included the use of disag-
gregating agents such as guanidinium, detergents and high salt
solutions (data not shown). However, a product with the same
electrophoretic mobility as the synthetic peptide was recog-
nised by SMAP antiserum only after treatment of the chro-
matographic sample with 20% DMSO (Fig. 7A). Similar re-
sults were obtained by resuspending SMAP eluate in AAU
loading bu¡er in the presence of 10% (w/v) 3-cholamidopro-
pyldimethylammonio-1-propane sulphonate. The separation
of this sample under disaggregating conditions allowed the
detection of a faint band with electrophoretic mobility similar
to that of synthetic SMAP-29 (Fig. 7B).
To test the antimicrobial activity of the recombinant pep-
tide, a gel overlay assay was done. This approach was used to
demonstrate that SMAP-29 was functional and active after
separation from the protein complex. The electrophoretic
run under denaturing conditions separated the recombinant
peptide disaggregated from the protein complex, while the
transfer over a bacterial layer evidenced a bacterial growth
inhibition area (Fig. 7C, lane 2) corresponding to the band
of transgenic SMAP revealed by Western blotting (Fig. 7A)
and similar to that obtained using the synthetic SMAP-29
molecule (Fig. 7C, lane 4). Conversely, the association of
transgenic peptide with plant proteins resulted in a loss of
bactericidal activity, as demonstrated by the lack of bacterial
growth inhibition area in the overlay gel assay for the sample
corresponding to SMAP eluate not disaggregated by DMSO
treatment (Fig. 7C, lane 1). The ability of some plant proteins
to strongly interact with SMAP-29 may thus be of some con-
cern when purifying this peptide from transgenic plants. The
Fig. 6. Binding of synthetic SMAP-29 to plant proteins. SMAP-29
incubated in the presence of untransformed tobacco protein extract
was separated onto 10^20% SDS^PAGE and analysed by Western
blotting. Lane 1: 200 ng of SMAP-29; lane 2: untransformed plant
crude extract incubated with 200 ng of SMAP-29; lane 3: untrans-
formed plant crude extract; lane 4: SMAP eluate puri¢ed from
transgenic plant extract; M: molecular size marker.
Fig. 7. Detection of disaggregated transgenic SMAP-29 peptide and evaluation of its antimicrobial activity. A: Western blotting of protein sam-
ple incubated in the presence of 20% DMSO, mixed to loading bu¡er and separated onto 10^20% SDS^PAGE. Lane 1: transgenic SMAP elu-
ate; lane 2: DMSO-treated transgenic SMAP eluate; lane 3: DMSO-treated untransformed plant eluate; lane 4: synthetic SMAP-29; M: mo-
lecular size marker. Alternatively, (B) transgenic SMAP eluate was separated onto denaturing 18% AAU^PAGE. Lane 1: synthetic SMAP-29;
lane 2: transgenic SMAP eluate; lane 3: untransformed plant eluate; M: molecular size marker. C: Antimicrobial activity of transgenic
SMAP-29 detected by overlay gel assay. Lane 1: transgenic SMAP eluate; lane 2: DMSO-treated transgenic SMAP eluate; lane 3: DMSO-
treated untransformed plant eluate; lane 4: synthetic SMAP-29; M: molecular size marker. D: Western blotting analysis of £ow-through and
column stripping fractions collected during transgenic plant extract chromatographic puri¢cation. FT: £ow-through sample was the protein ex-
tract recovered after loading onto chitin-puri¢cation column; CS: column stripping sample after transgenic SMAP elution; M: molecular size
marker.
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puri¢cation problems that we faced may be related to struc-
tural features of SMAP-29, as suggested by the fact that treat-
ment of the protein complex with a strong disaggregating
agent resulted in disruption of the complex and release of a
fully functional transgenic peptide of the same molecular size
as the synthetic SMAP-29. Conversely, early steps in the in-
tein-mediated expression mechanism were not problematic
and resulted in the correct cleavage of the fusion protein, as
demonstrated by the fact that the intein^CBD tail was recov-
ered after column stripping and detected using CBD-speci¢c
antiserum (Fig. 7D, CS). Moreover, in the £ow-through sam-
ple (Fig. 7D, FT), only aspeci¢c bands with a MW lower than
fusion protein size were detected. This indicates that the bind-
ing capacity of the chitin column allowed an almost complete
recovery of the fusion protein from the total protein extracts.
3.3. Conclusions
This work provides the ¢rst evidence of the production of a
recombinant protein in transgenic plants by exploiting the
intein-mediated self-cleavage mechanism. This may represent
a proof-of-concept study for a new biotechnological strategy
for producing pharmaceutical polypeptides in plants. The re-
sults demonstrate that transgenic tobacco plants are able to
produce a target peptide as a fusion protein with intein^CBD;
this can be puri¢ed by a⁄nity chromatography and the pep-
tide released by inducing intein self-cleaving with nucleophilic
agents. Although the system needs to be optimised according
to the chemical features of the target product, these prelimi-
nary results clearly demonstrate that the self-cleaving intein
expression is a promising strategy for producing peptides of
pharmaceutical interest. Research is now in progress to in-
crease the transgenic protein recovery rates and verify the
applicability of the intein-based system to the synthesis of
larger heterologous proteins in plants. In this case the e⁄-
ciency of this puri¢cation strategy will be optimised in order
to keep the correct protein folding and cleavage e⁄ciency in
the presence of multiple disulphide bonds.
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